---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-290779"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2023-12-07T23:59:59+00:00"
generated_at: "2026-06-07T16:03:29.000859+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vanda acquires U.S. and Canadian rights to PONVORY for $100M upfront

## Summary
- Acquired exclusive U.S. and Canadian rights to PONVORY (ponesimod), a once-daily oral S1P1R modulator for relapsing multiple sclerosis.
- Upfront cash payment of $100 million to Janssen (Johnson & Johnson); transaction closed December 7, 2023.
- Janssen will continue operations under a transitional services agreement while Vanda assumes regulatory and supply responsibility.
- Vanda CEO highlights PONVORY as a versatile immune-response modifier with potential application in autoimmune disorders beyond MS.

## SEC filing metadata
- accession: 0001193125-23-290779
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2023-12-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000119312523290779/0001193125-23-290779-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000119312523290779/d635973d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-290779
- JSON: https://secwatch.observer/filing/0001193125-23-290779.json
- Plain text: https://secwatch.observer/filing/0001193125-23-290779.txt

## Key facts
- M&A Transactions
  Vanda Pharmaceuticals Inc. completed an acquisition involving Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company for $100 million (closed 2023-12-07).
  - Action: acquisition
  - Counterparty: Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company
  - Consideration: $100 million
  - Closing: 2023-12-07
  source text: Vanda made an upfront payment of $100 million to Janssen as consideration for the Purchased Assets.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347178/000119312523290779/0001193125-23-290779-index.htm
- Material Agreements
  Vanda Pharmaceuticals Inc. entered into Purchase Agreement with Actelion Pharmaceuticals Ltd. (Janssen, a Johnson & Johnson Company) valued at $100 million (effective 2023-12-07).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Actelion Pharmaceuticals Ltd. (Janssen, a Johnson & Johnson Company)
  - Value: $100 million
  - Effective: 2023-12-07
  source text: On December 7, 2023, Vanda Pharmaceuticals Inc. (“Vanda”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Actelion Pharmaceuticals Ltd. (“Janssen”), a Johnson & Johnson Company, pursuant to which Vanda acquired from Janssen the U.S. and Canadian rights for PONVORY ® (ponesimod).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347178/000119312523290779/0001193125-23-290779-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.